Clinical significance of HPV test

1. Muñoz N, Bosch FX, de Sanjose S et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348(6): 518-527.

2. American College of Obstetricians and Gynecologists. Human Papillomavirus. ACOG Practice Bulletin 2005; 61. (???opraveno: ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 61, April 2005. Human papillomavirus. Obstet Gynecol. 2005 Apr;105(4):905-18.)

3. Cuzick J, Sasieni P, Davies P at al. A systematic review of the role of human papillomavirus testing within a cervical screening programme. Health Technol Assess 1999; 3: 1-196.

4. Herrero R, Hildesheim A, Bratti C et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000; 92(6): 464-474.

5. Moscicki AB. Cervical cytology screening in teens. Curr Womens Health Rep 2003; 3: 433-437.

6. Monsonego J, Bosch FX, Cuorsaget P et al. Cervical cancer control priorities and new directions. Int J Cancer 2004; 108: 309-333.

7. Schneider A, Hoyer H, Lota B et al. Screening for high-grade cervical intraepithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int J Cancer 2000; 89: 529-534.

8. Schiffman M, Khan MJ, Solomon D et al. A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst 2005; 97(2):147-150.

9. Koutsky LA, Holmes KK, Critchlow CW et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992; 327(18): 1272-1278.

10. Lorincz AT, Richart RM. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch Pathol Lab Med 2003; 127(8): 959-968.

11. Bosch FX, Lorincz A, Muñoz N et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-265.

12. Wright TC jr, Cox JT, Massad LS et al. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA 2002; 287: 2120-2129.

13. ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003; 188: 1383-1392.

14. Clavel C, Cucherousset J, Lorenzato M et al. Negative human papillomavirus testing in normal smears selects a population at low risk for developing high-grade cervical laesions. Br J Cancer 2004; 90: 1803-1808.

15. Wright TC jr, Schiffman M, Solomon D et al. Interim guidance on the use of HPV DNA testing as an adjunct to cervical cytology. Obstet Gynecol 2004; 103: 304-309.

16. Denny L, Kuhn L, Pollack A et al. Evaluation of alternative methods of cervical cancer screening for resource-poor settings. Cancer 2000; 89: 826-833.

17. Zielinski GD, Bais AG, Helmerhorst TJ et al. HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis. Obstet Gynecol Surv 2004; 59: 543-553.

18. Ronnett BM, Manos MM, Ransley JE et al. Atypical glandular cells of undetermined significance (AGUS): cytopathologic features, histopathologic results, and human papillomavirus DNA detection. Human Pathol 1999; 30(7): 816-825.